Non-Regulatory

September 17, 2013

New molecular imaging agents being developed for fluorescence-guided brain cancer surgery

Solna, Sweden, September 17, 2013. Dartmouth, LI-COR and Affibody receive NIH grant for development and translation of imaging agents for fluorescence-guided surgery.

Read more

Non-Regulatory

August 29, 2013

Interim Report – January to June 2013

Affibody Medical AB (publ) (“Affibody” or “the Company”), a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™,...

Read more

Non-Regulatory

July 23, 2013

Kallelse till extra bolagsstämma

Aktieägarna i Affibody Holding AB (publ) kallas härmed till extra bolagsstämma tisdagen den 20 augusti 2013 kl 10.00 i Advokatfirman Lindahls lokaler, Mäster Samuelsgatan 20, Stockholm.

Read more

Non-Regulatory

June 28, 2013

Resolutions from Affibody’s Annual General Meeting (AGM)

Solna, Sweden, June 28, 2013. The Affibody Holding AB’s (publ) (Affibody) AGM convened earlier today in Solna and voted in favour of the resolutions proposed at the meeting,...

Read more

Non-Regulatory

June 25, 2013

Affibody AB and Daiichi Sankyo enter into a License Agreement regarding the Albumod™ platform

Solna, Sweden, June 25, 2013. Affibody is pleased to announce a collaboration with Daiichi Sankyo Company Limited (hereinafter Daiichi Sankyo; headquartered in Chuo Ward, Tokyo, TSE 4568).

Read more

Non-Regulatory

June 15, 2013

Interim Report – January to March 2013

Affibody Holding AB (publ) (“Affibody” or “the Company”), a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™,...

Read more

Non-Regulatory

May 31, 2013

Kallelse till årsstämma

Aktieägarna i Affibody Holding AB (publ) kallas härmed till årsstämma fredagen den 28 juni 2013 kl 10.00 i bolagets lokaler, Gunnar Asplunds allé 24, Solna.

Read more

Non-Regulatory

May 22, 2013

Affibody AB receives SwedenBIO award 2013

Solna, Sweden, May 22, 2013. Affibody wins SwedenBIO Award 2013 for its unique business model.

Read more

Non-Regulatory

April 30, 2013

First Patient Included in PET Imaging Study of HER2 Expression in Metastatic Breast Cancer

Solna, Sweden, April 30, 2013. Affibody is pleased to announce that the first patient has been enrolled in a clinical study to evaluate ABY-025 for PET imaging of HER2...

Read more